Showing results (121-130 of 409) with videos related to

Sort By:
Pageof 41
Molecular Therapy. Oncology|December 16, 2025
Efficacy and safety of BRAF-MEK inhibitors in treatment of Chinese patients with papillary craniopharyngioma: A retrospective cohort studyRui Han, Xiaorong Yan, Boyuan Yao, et al.
Molecular Therapy. Oncology|December 1, 2025
Mechanistic and functional characterization of ABTB2 as a novel target for pancreatic cancer therapyNan Lyu, Olamide T Olaoba, Qiongling Wang, et al.
Molecular Therapy. Oncology|December 1, 2025
An oncolytic herpesvirus expressing a CXCR4 antagonist interferes with glioblastoma cells' stemness features and migrationPaolo D'arrigo, Maxime Dubois, Judit Sanchez Gil, et al.
Molecular Therapy. Oncology|December 1, 2025
Clinical translation of TLR agonist-modified silicified cancer cell therapy supported by humanized mouse modelsMara P Steinkamp, Danielle Burke, Madigan Morrison, et al.
Molecular Therapy. Oncology|December 1, 2025
CD19 CAR T cell therapy BY19 for pediatric and adult patients with relapsed or refractory B cell neoplasms in Belarus: Phase 1 trialMikalai Katsin, Dmitri Dormeshkin, Alexandr Migas, et al.
Molecular Therapy. Oncology|January 6, 2025
Clinical value of circulating splicing factors in prostate cancer: SRRM1 as a novel predictive biomarker and therapeutic targetAntonio J Montero-Hidalgo, Enrique Gómez-Gómez, Manuel Galán-Cañete, et al.
Molecular Therapy. Oncology|January 6, 2025
An oncolytic HAdV-5 with reduced surface charge combines diminished toxicity and improved tumor targetingFrederik Wienen, Robin Nilson, Ellen Allmendinger, et al.
Molecular Therapy. Oncology|March 7, 2025
Enhancement of radio-sensitivity by inhibition of Janus kinase signaling with oclacitinib in canine tumor cell linesRyo Owaki, Kenji Hosoya, Tatsuya Deguchi, et al.
Molecular Therapy. Oncology|December 6, 2024
Targeting cancer stem cells by TPA leads to inhibition of refractory sarcoma and extended overall survivalKarina Galoian, Daniel Bilbao, Carina Denny, et al.
Molecular Therapy. Oncology|March 4, 2025
Preclinical study of inetetamab combined with atezolizumab to synergistically inhibit HER2 and PD-L1 in the treatment of ovarian cancerFeiquan Ying, Xuyang Zhou, Mengqing Chen, et al.
Pageof 41